Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

afinitor

FDA approves new indication for Novartis’ Afinitor

February 29, 2016
Research and Development, Sales and Marketing Afinitor, Novartis

Novartis’ cancer drug Afinitor (everolimus) has been granted FDA approval in a new indication: for the treatment of adult patients …

News
novartis_pic

Novartis drug PKC412 gets Breakthrough designation for AML

February 19, 2016
Medical Communications, Research and Development FDA, Novartis, acute myeloid leukaemia

Novartis’ PKC412 (midostaurin)  has become the latest in a sequence of FDA Breakthrough Therapy designations awarded this week- bagging the …

News
fda

Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Feature
incyte

Incyte to stop Jakafi pancreatic, colorectal cancer drug trials

February 11, 2016
Research and Development Incyte, Jakafi, Jakavi, Novartis, Pancreatic cancer, colorectal cancer

Incyte said today that it is terminating its JANUS clinical trial programme testing blood cancer drug Jakafi in solid tumours …

News
sandoz_building

EMA accepts Sandoz Neulasta biosimilar for review

February 11, 2016
Research and Development Amgen, Neulasta, Novartis, Sandoz

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …

News

NICE publishes new myeloma guidance

February 10, 2016
Medical Communications, Research and Development Farydak, Novartis, multiple myeloma

NICE has set out best practice for the diagnosis, monitoring and treatment of myeloma, in new guidelines published today. Myeloma …

News

Novartis says CDF proposals place “unreasonable” risk on pharma

February 10, 2016
Medical Communications, Research and Development, Sales and Marketing Cancer Drugs Fund, NHS England, NICE, Novartis

Novartis has criticised some of the proposed changes to the way in which the UK Cancer Drugs Fund (CDF) is …

News
sun_pharma_logo

Sun Pharma takes on Novartis in the US with generic Glivec

February 2, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gleevec, Novartis, Sun Pharma

Mumbai-based drug manufacturer Sun Pharma has launched a generic version of Glivec, for the same indications for which the former …

News
Joseph Jimenez

Novartis braces for cuts after mixed 2015 performance

January 28, 2016
Sales and Marketing Novartis, financial results, revenue, sales

Net sales at Novartis fell by 5% in 2015 – prompting the company to make billion-dollar changes to its business …

News
alcon_ceo_mike_ball

Former Hospira boss joins Alcon as Novartis makes senior leadership changes

January 27, 2016
Novartis

Swiss firm Novartis has announced several leadership changes, effective February 1, 2016.In a briefing to present the company’s financial results, …

Appointment
Arzerra

Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

News
cosentyx

Two new US approvals for Novartis’ Cosentyx

January 18, 2016
Research and Development, Sales and Marketing Cosentyx, Novartis

Novartis has won FDA approval for Cosentyx (secukinumab) for the treatment of two new indications – adults with active ankylosing …

News
Eisai

Eisai submits new cancer combo to EMA for approval

January 12, 2016
Sales and Marketing Afinitor, EMA, Eisai, Lenvima, MAA, Novartis, everolimus, lenvatinib

Eisai has submitted a new Marketing Authorisation Application to the EMA for the combination of Lenvima and Novartis’ Afinitor for …

News
Horsham

Former Novartis site to be developed into science park

January 12, 2016
Manufacturing and Production Employment, Jobs, Life science, Novartis, West Sussex, science park

Work has begun to transform a 20-acre site that formerly housed Novartis, in West Sussex, into a world renowned centre …

News
novartis_window

Novartis expands immuno-oncology programme

January 11, 2016
Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026